NCT07373834Recruiting
Tirzepatide and Muscle Outcomes in Obesity
Effects of Tirzepatide on Skeletal Muscle in Obesity
Source: ClinicalTrials.gov · Last updated 28 Jan 2026
Brief summary (registry, in English)
This study is evaluating whether a dual glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist, tirzepatide, can affect the function, structure and metabolism of skeletal muscles in adults with obesity. Participants, premenopausal females with obesity, will receive either tirzepatide or placebo over 24 weeks. Researchers will assess body weight, body composition, muscle strength and functional performance, neuromuscular function and will perform muscle biopsies before and after treatment to study molecular and histological changes following treatment. The goal of this study is to investigate the effects of tirzepatide on skeletal muscle function, quantity, quality and metabolism in adults with obesity as well as clarify the molecular and structural adaptations in skeletal muscle during tirzepatide-induced weight loss, addressing an important gap in understanding the impact of incretin-based therapies on muscle health.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- First submitted
- 5 Dec 2025
- Start date
- Jan 2026
- Primary completion date
- Dec 2026
- Lead sponsor
- University Medical Centre Ljubljana
- Diseases
- Obesity
- NCT number
- NCT07373834
What you commit to
- Study type: Interventional
- Planned participants: 30
- From Jan 2026 to the primary completion date, Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Current treatment with metformin or systemic corticosteroids
Other illness
- Diabetes
- Personal history of malignancy
- Personal history of pancreatitis
- Personal history of major depressive episodes
- Personal history of myopathy
- Personal or family history of medullary thyroid carcinoma
Other
- Sarcopenic obesity
- Pregnancy or lactation
- Postmenopausal status
- Immobility
Who the study is looking for
- Female sex
- Age between 18 and 50 years
- BMI between 30 kg/m² and 40 kg/m²
- Stable body weight within the three months preceding study enrolment (defined as ≤ 5% change)
- No prior pharmacological or surgical interventions for obesity treatment
- Commitment to use barrier contraception and absence of plans for pregnancy within 8 months following enrolment
Age in the registry: 18 years to 50 years · Sex: Female · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Department of Endocrinology, Diabetes and Metabolic Diseases, University Medical Centre Ljubljana Coordinator of this site? Confirm its status | Ljubljana | Slovenia | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.